Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep 7;25(1):334.
doi: 10.1186/s12875-024-02579-y.

Enhancing hypertension education of community health extension workers in Nigeria's federal capital territory: the impact of the extension for community healthcare outcomes model on primary care, a quasi-experimental study

Affiliations
Clinical Trial

Enhancing hypertension education of community health extension workers in Nigeria's federal capital territory: the impact of the extension for community healthcare outcomes model on primary care, a quasi-experimental study

Abigail S Baldridge et al. BMC Prim Care. .

Abstract

Background: Healthcare workers (HCWs) including community health extension workers (CHEWs) in the Federal Capital Territory, Nigeria participated in a hypertension training series following the Extension for Community Healthcare Outcomes (ECHO) model which leverages technology and a practical peer-to-peer learning framework to virtually train healthcare practitioners. We sought to evaluate the patient-level effects of the hypertension ECHO series.

Methods: HCWs from 12 of 33 eligible primary healthcare centers (PHCs) in the Hypertension Treatment in Nigeria Program (NCT04158154) were selected to participate in a seven-part hypertension ECHO series from August 2022 to April 2023. Concurrent Hypertension Treatment in Nigeria Program patient data were used to evaluate changes in hypertension treatment and control rates, and adherence to Nigeria's hypertension treatment protocol. Outcomes were compared between the 12 PHCs in the ECHO program and the 21 which were not.

Results: Between July 2022 and June 2023, 16,691 PHC visits were documented among 4340 individuals (ECHO: n = 1428 [33%], non-ECHO: n = 2912 [67%]). Patients were on average (SD) 51.5 (12.0) years old, and one-third were male (n = 1372, 32%) with no differences between cohorts in either characteristic (p ≥ 0.05 for both). Blood pressures at enrollment were higher in the ECHO cohort compared to the non-ECHO cohort (systolic p < 0.0001 and diastolic p = 0.0001), and patients were less likely to be treated with multiple medications (p < 0.0001). Treatment rates were similar at baseline (ECHO: 94.0% and Non-ECHO: 94.7%) and increased at a higher rate (interaction p = 0.045) in the ECHO cohort over time. After adjustment for baseline and within site variation, the difference was attenuated (interaction p = 0.37). Over time, control rates increased and medication protocol adherence decreased, with no differences between cohorts. Staffing levels, adult patient visits, and rates of hypertension screening and empanelment were similar between ECHO and non-ECHO cohorts (p ≥ 0.05 for all).

Conclusions: The ECHO series was associated with moderately increased hypertension treatment rates and did not adversely affect staffing or clinical capacity among PHCs in the Federal Capital Territory, Nigeria. These results may be used to inform strategies to support scaling hypertension education among frontline HCWs throughout Nigeria, and use of the ECHO model for CHEWs.

Trial registration: The Hypertension Treatment in Nigeria Program was prospectively registered on November 8, 2019 at www.

Clinicaltrials: gov (NCT04158154; https://clinicaltrials.gov/ct2/show/NCT04158154 ).

Keywords: Education; Hypertension; Implementation; Primary care; Qualitative.

PubMed Disclaimer

Conflict of interest statement

MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. LRH served as a Guest Editor for ‘The role of community health workers in primary care’ Collection.

Figures

Fig. 1
Fig. 1
Observed Treatment (A), Control (B), and Medication Protocol Adherence (C) Rates and 95% Confidence Intervals Over Time by Extension for Community Healthcare Outcomes Group. The proportion of empaneled patients who were treated, controlled, and prescribed medications following the Nigeria hypertension protocol are shown based on the timing of their visits to 12 primary healthcare centers which were selected to participate in the Extension for Community Healthcare Outcomes program and 21 which were not. Results are shown as a proportion and accompanying 95% confidence interval using patient level data from the Nigeria Hypertension Treatment Program registry
Fig. 2
Fig. 2
Clinic Caseload (A) and Cascade of Hypertension Evaluation (B), Diagnosis (C), and Empanelment (D) based on Quarterly Supportive Supervision Visits. Site supervision data from the Nigeria Hypertension Treatment Program were used to summarize clinic caseload and hypertension services. Data are from the immediate prior quarter (Q2 2022) and each quarter during (Q3 2022 to Q2 2023) the hypertension Extension for Community Healthcare Outcomes program. The site supervision protocol included visiting each site once per quarter, and all visits occurred as planned except for one. During the visit, site registry information was used to calculate the number of adult patients visiting the clinic per day. The number of those adults who had their blood pressure checked was documented, along with the number of adults who had high blood pressure and the number who were newly registered in the Nigeria Hypertension Treatment Program

References

    1. Vollset SE, Goren E, Yuan CW, Cao J, Smith AE, Hsiao T, et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of Disease Study. Lancet. 2020;396(10258):1285–306. 10.1016/S0140-6736(20)30677-2 - DOI - PMC - PubMed
    1. Abubakar I, Dalglish SL, Angell B, Sanuade O, Abimbola S, Adamu AL, et al. The Lancet Nigeria Commission: investing in health and the future of the nation. Lancet. 2022;399(10330):1155–200. 10.1016/S0140-6736(21)02488-0 - DOI - PMC - PubMed
    1. Ogah OS, Orimolade OA, Jinadu TO. Cardiovascular diseases in Nigeria: current status, threats, and opportunities. Circulation. 2023;148(19):1441–4. 10.1161/CIRCULATIONAHA.123.063671 - DOI - PubMed
    1. Murthy GV, Fox S, Sivasubramaniam S, Gilbert CE, Mahdi AM, Imam AU, et al. Prevalence and risk factors for hypertension and association with ethnicity in Nigeria: results from a national survey. Cardiovasc J Afr. 2013;24(9–10):344–50. 10.5830/CVJA-2013-058 - DOI - PMC - PubMed
    1. Adeloye D, Basquill C, Aderemi AV, Thompson JY, Obi FA. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42. 10.1097/HJH.0000000000000413 - DOI - PubMed

Substances

Associated data

LinkOut - more resources